Combining microenvironment normalization strategies to improve cancer immunotherapy
Significance
Immunotherapy has changed the standard of care in cancer treatment, but an estimated 87% of patients currently do not derive long-term benefit from immune checkpoint blocker monotherapy. Therefore, new therapeutic strategies are needed to improve the response rates in patients who are resistant to immune checkpoint inhibition. We have developed a mathematical framework to determine how tumor microenvironment normalization strategies—specifically, vascular and stroma normalization—might improve immunotherapy efficacy. By incorporating complex interactions among various types of cancer cells, immune cells, stromal cells, and the vasculature, as well as physical mechanisms, we provide guidelines for designing effective combinatorial therapeutic strategies and point out areas for future investigation.
Top-30
Journals
|
2
4
6
8
10
|
|
|
Cancers
10 publications, 4.85%
|
|
|
Frontiers in Oncology
9 publications, 4.37%
|
|
|
Frontiers in Immunology
7 publications, 3.4%
|
|
|
Journal of Controlled Release
7 publications, 3.4%
|
|
|
Journal of Theoretical Biology
5 publications, 2.43%
|
|
|
Advanced healthcare materials
4 publications, 1.94%
|
|
|
Nature Reviews Cancer
4 publications, 1.94%
|
|
|
ACS Nano
4 publications, 1.94%
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
4 publications, 1.94%
|
|
|
International Journal of Molecular Sciences
3 publications, 1.46%
|
|
|
Journal of Experimental and Clinical Cancer Research
3 publications, 1.46%
|
|
|
Nature Communications
3 publications, 1.46%
|
|
|
Biomedicine and Pharmacotherapy
3 publications, 1.46%
|
|
|
Biomaterials Science
3 publications, 1.46%
|
|
|
Journal for ImmunoTherapy of Cancer
3 publications, 1.46%
|
|
|
Biomaterials
3 publications, 1.46%
|
|
|
Biomedicines
2 publications, 0.97%
|
|
|
Frontiers in Cell and Developmental Biology
2 publications, 0.97%
|
|
|
Frontiers in Bioengineering and Biotechnology
2 publications, 0.97%
|
|
|
Communications Medicine
2 publications, 0.97%
|
|
|
Journal of Drug Delivery Science and Technology
2 publications, 0.97%
|
|
|
Advanced Materials
2 publications, 0.97%
|
|
|
Advanced Science
2 publications, 0.97%
|
|
|
Small
2 publications, 0.97%
|
|
|
Clinical Cancer Research
2 publications, 0.97%
|
|
|
European Journal of Medicinal Chemistry
2 publications, 0.97%
|
|
|
Biochimica et Biophysica Acta - Reviews on Cancer
2 publications, 0.97%
|
|
|
PLoS Computational Biology
2 publications, 0.97%
|
|
|
Frontiers in Chemistry
1 publication, 0.49%
|
|
|
2
4
6
8
10
|
Publishers
|
5
10
15
20
25
30
35
40
45
50
|
|
|
Elsevier
49 publications, 23.79%
|
|
|
Springer Nature
36 publications, 17.48%
|
|
|
Wiley
24 publications, 11.65%
|
|
|
Frontiers Media S.A.
23 publications, 11.17%
|
|
|
MDPI
19 publications, 9.22%
|
|
|
Cold Spring Harbor Laboratory
8 publications, 3.88%
|
|
|
Taylor & Francis
7 publications, 3.4%
|
|
|
American Chemical Society (ACS)
6 publications, 2.91%
|
|
|
American Association for Cancer Research (AACR)
5 publications, 2.43%
|
|
|
Royal Society of Chemistry (RSC)
4 publications, 1.94%
|
|
|
BMJ
4 publications, 1.94%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
4 publications, 1.94%
|
|
|
SAGE
3 publications, 1.46%
|
|
|
American Medical Association (AMA)
2 publications, 0.97%
|
|
|
Public Library of Science (PLoS)
2 publications, 0.97%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.49%
|
|
|
PeerJ
1 publication, 0.49%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 0.49%
|
|
|
American Society for Biochemistry and Molecular Biology
1 publication, 0.49%
|
|
|
The Endocrine Society
1 publication, 0.49%
|
|
|
Portland Press
1 publication, 0.49%
|
|
|
Oxford University Press
1 publication, 0.49%
|
|
|
IMR Press
1 publication, 0.49%
|
|
|
5
10
15
20
25
30
35
40
45
50
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.